摘要
目的比较齐拉西酮序贯疗法与利培酮治疗精神分裂症的临床疗效。方法选取医院2021年9月至2022年9月收治的精神分裂症患者98例,随机分为观察组和对照组,各49例。对照组患者予以利培酮口服,观察组患者采用齐拉西酮序贯疗法。两组患者均治疗6个月。结果治疗后,观察组患者的空腹血糖、甘油三酯、总胆固醇水平均显著低于对照组;认知功能、自卑、自尊评分均显著优于对照组(P<0.05)。结论相比利培酮,齐拉西酮序贯疗法治疗精神分裂症可更好地改善患者的糖脂代谢指标、认知功能、自卑及自尊程度。
Objective To compare the clinical effects of ziprasidone sequential therapy and risperidone in the treatment of schizophrenia.Methods A total of 98 patients with schizophrenia admitted to the hospital from September 2021 to September 2022 were selected and randomly divided into the observation group and the control group,with 49 cases in each group.The patients in the control group were given oral risperidone,while the patients in the observation group were treated with ziprasidone sequential therapy.The patients in the two groups were treated for six months.Results After treatment,the fasting blood glucose,triglycerides,and total cholesterol levels in the observation group were significantly lower than those in the control group;the cognitive function,inferiority,and self-esteem scores were significantly better than those in the control group(P<0.05).Conclusion Compared with risperidone,ziprasidone sequential therapy can better improve the glycolipid metabolism indicators,cognitive function,inferiority and self-esteem of patients with schizophrenia.
作者
曹大煜
刘虹佳
CAO Dayu;LIU Hongjia(Tianjin Anding Hospital,Tianjin,China 300222)
出处
《中国药业》
CAS
2024年第S01期73-75,共3页
China Pharmaceuticals
关键词
齐拉西酮
序贯疗法
利培酮
精神分裂症
糖脂代谢
认知功能
zirasidone
sequential therapy
risperidone
schizophrenia
glycolipid metabolism
cognitive function
